Greater Dissociation of Apolipoprotein B and LDL Cholesterol Targets in Diabetes Versus Nondiabetes Patients Receiving Lipid-Lowering Therapy

      Synopsis: Recent reports suggest apolipoprotein B (ApoB) is a good predictor of coronary risk. Low-density lipoprotein cholesterol (LDL-C) may underestimate the number of atherogenic particles in certain patients with elevated levels of small dense LDL particles and remnant particles. To this end, the American Diabetes Association/American College of Cardiology treatment guidelines for cardiometabolic patients, including patients with diabetes, recommend ApoB targets <90 mg/dL and <80 mg/dL for high-risk and very high-risk patients, respectively.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect